Phase II open label pilot study of V3381 in chronic cough

Vernalis (R&D) Ltd (UK)0 个研究点目标入组 10 人开始时间: 2010年12月13日最近更新: 2020年1月6日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 10

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•1. Male or female 18 - 75 years of age
•2. Females must be of non child-bearing potential (i.e., surgically sterilised or greater than 1 year post-menopause). Male patients who are sexually active with a female partner of child-bearing potential must agree to use a barrier method of contraception for the duration of the study.
•3. Chronic cough (greater than 8 weeks)
•4. Normal chest X-ray
•5. Normal lung function
•6. Idiopathic or treatment resistant cough, defined as a cough for which no objective evidence of an underlying trigger can be determined after investigation (idiopathic) or a cough that is unresponsive to 8 weeks of targeted treatment for identified underlying triggers including reflux disease, asthma and post-nasal drip (treatment-resistant)

排除标准

•1. Recent upper respiratory tract infection (less than 4 weeks)
•2. Pregnancy/breast-feeding
•3. Current smokers or ex-smokers with less than 6 months abstinence or cumulative history of greater than 10 pack years
•4. Current treatment with angiotensin converting enzyme (ACE) inhibitors
•5. Drug or alcohol abuse
•6. Uncontrolled hypertension (i.e., greater than 140/90 mmHg despite adequate medical therapy)
•7. Any cardiovascular condition that would be a contra-indication to the use of sympathomimetic amines (e.g. active angina)
•8. Any clinically significant neurological disorder
•9. Prior renal transplant, current renal dialysis
•10. Any clinically significant or unstable medical or psychiatric condition that would interfere with the patient's ability to participate in the study
•11. Increased risk of seizures (defined as a history of seizure disorder, family history of seizures and history of head trauma that resulted in loss of consciousness or concussion)
•12. Any malignancy in the past 2 years (with the exception of basal cell carcinoma)
•13. Use of opioids, anticonvulsants, antidepressants (particularly monoaminde oxidase [MAO] inhibitors). Patients currently taking drugs in these classes for chronic cough may have them discontinued prior to entry into the study. Selective serotonin reuptake inhibitors should be discontinued at least 4 weeks prior to study; all other prohibited medications should be discontinued 2 weeks prior to study. Patients should not be taking NMDA-receptor antagonists or sympathomimetics during the study period.
•14. Any clinically significant abnormal laboratory test result(s)
•15. Serum creatinine laboratory value greater than 1.5 x upper limit of normal (ULN) reference range (after adjustment for age) or estimated creatinine clearance less than 60 ml/min
•16. Total bilirubin greater than upper limit of normal reference range (with the exception of Gilbert's syndrome) and/or alanine transaminase (ALT) greater than 1.5 times upper limit of normal reference ranges (after adjustment for age)

研究者

发起方

Vernalis (R&D) Ltd (UK)

相似试验

进行中（未招募）

不适用

Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients attending a Specialist Clinic - Phase II Open-Label Pilot Study of V3381 in Chronic CoughMedDRA version: 9.1Level: LLTClassification code 10066656Term: Chronic coughTreatment resistant and Idiopathic Chronic Cough

EUCTR2009-011525-13-GBVernalis (R&D) Limited20

进行中（未招募）

1 期

An early access study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer.Metastatic colorectal cancerMedDRA version: 19.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-002311-18-ESaboratorios Servier S. L.1,000

进行中（未招募）

1 期

An early access study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer.

EUCTR2016-002311-18-PTInstitut de Recherches Internationales Servier1,000

进行中（未招募）

1 期

EUCTR2016-002311-18-FRInstitut de Recherches Internationales Servier1,000

进行中（未招募）

1 期

An early access study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer.Metastatic colorectal cancerMedDRA version: 20.0 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-002311-18-HRInstitut de Recherches Internationales Servier1,000